Clinical utility of liquid biopsy in bladder cancer: The beginning of a . . . Bladder cancer treatment is highly complex, often requiring a multi-modal approach contingent upon both the tumor's stage and grade Among newly diagnosed bladder cancer patients, non-muscle invasive bladder cancer (NMIBC) constitutes approximately 70 % of cases, while muscle invasive bladder cancer (MIBC) accounts for the remaining 30 %
Liquid biopsies for bladder cancer - PMC - National Center for . . . A liquid biopsy may also capture disease heterogeneity better than a solid biopsy which only samples a single part of a single tumour Clearly, in vivo, The bladder cancer community should now focus on selecting the best biomarkers, optimising assay sensitivity, and large-scale validation of these novel tests
Liquid biopsy in bladder cancer: State of the art and future . . . Bladder cancer is the most common malignancy of the urinary tract Cystoscopy represents the gold standard in the diagnosis of suspicious bladder lesions which represents an alternative diagno … Liquid biopsy in bladder cancer: State of the art and future perspectives Crit Rev Oncol Hematol 2022 Feb:170:103577 doi: 10 1016 j critrevonc
Urine‐based liquid biopsy in bladder cancer: Opportunities and . . . Liquid biopsy is a non-invasive test for the analysis of biomarkers in biological fluids (e g , saliva, urine, blood, etc ) and is promising to replace or reduce use of tissue biopsy in cancer diagnosis and surveillance 8 As previously reported, tissue samples may not fully represent tumour heterogeneity based on the location and accessibility
Liquid biopsy in bladder cancer: State of the art and future . . . The following terms with synonyms were combined in a title-abstract search to retrieve all relevant publications: bladder cancer, non-muscle-invasive bladder cancer, urinary biomarker, liquid biopsy Articles were screened by two independent reviewers in order to select studies, extract data and remove duplicates
Liquid Biopsy: A Viable Option for Accurate Diagnosis and. . . : Journal . . . Another emerging role of liquid biopsy in diagnosing bladder cancer is by analyzing immunofluorescence markers such as bladder cancer antigen 1 (BLCA1), BLCA4, 5-aminolevulinic acid, and hexaminolevulinate, CTCs, and other urinary biomarkers such as bladder tumor antigen (TRAK) and nuclear matrix protein-22
Urine Liquid Biopsies for Bladder Cancer - Johns Hopkins Medicine With collaborators in the Southwest Oncology Group (SWOG), the Department of Urology at MD Anderson Cancer Center, and industry collaborators, McConkey has been leading efforts to use urine liquid biopsies to predict and track benefit from intravesical interferon gene therapy (with Adstiladrin) and the immune checkpoint inhibitor, atezolizumab
New Perspectives on the Role of Liquid Biopsy in Bladder Cancer . . . Keywords: liquid biopsy, bladder cancer, immunotherapy, precision medicine 1 Introduction Bladder cancer is the ninth most common cancer worldwide and the tumor most diagnosed in the urinary tract Its incidence is increasing, and it is particularly high in Western Europe and North America The main histological subtype is urothelial
Liquid Biopsy in Bladder Cancer - SpringerLink Fluid biopsy based on circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), exosome, and circulating RNA in blood and body fluids has gained attention Here, the recent findings and issues related to liquid biopsy in bladder cancer are discussed, with a focus on CTCs, ctDNA, urinary tumor DNA, exosome, and circulating RNA
Liquid biopsy in the clinical management of bladder cancer . . . - PubMed Introduction: The use of liquid biopsy on the blood from solid malignancies provides a convenient way of detecting actionable mutations, monitoring treatment response, detecting early recurrence and prognosticating outcomes The aim of this review is to discuss the current status and future direction of serum biomarkers in the clinical management of urinary bladder cancer